Skip to main content
BOTANIX PHARMACEUTICALS LTD logo

BOTANIX PHARMACEUTICALS LTD — Investor Relations & Filings

Ticker · BOT ISIN · AU000000BOT2 ASX Manufacturing
Open in API
Filings indexed 1,209 across all filing types
Latest filing 2017-11-13 AGM Information
Country AU Australia
Listing ASX BOT

About BOTANIX PHARMACEUTICALS LTD

https://botanixpharma.com/

Botanix Pharmaceuticals Ltd is a clinical-stage pharmaceutical company focused on the development and commercialization of novel topical treatments for serious skin conditions. The company utilizes its proprietary Permetrex™ skin delivery technology, which is designed to improve the delivery of active ingredients through the skin. Its primary product, Sofdra™ (sofpironium bromide), is an FDA-approved prescription topical gel for the treatment of primary axillary hyperhidrosis. The company's research and development pipeline also includes clinical-stage candidates for the treatment of acne, rosacea, and atopic dermatitis. Botanix aims to address significant unmet medical needs in dermatology by providing innovative therapeutic solutions with enhanced safety and efficacy profiles.

Recent filings

Filing Released Lang Actions
2017 Annual General Meeting Chairmans Address 4 pages 440.9KB
AGM Information Classification · 95% confidence The document is titled 'Botanix Pharmaceuticals 2017 Annual General Meeting Chairman’s Address' and is dated 14 November 2017. It is clearly a speech or address given by the Chairman at the company's Annual General Meeting (AGM). The content includes a welcome message, a review of the company's progress over the past year, and future plans, which are typical elements of a Chairman's address at an AGM. There is no detailed financial data, audit information, or regulatory filing content. The document is not a full annual report or financial statement but rather a presentation or speech given at the AGM. Therefore, the document fits the category of AGM Information (AGM-R). The document length (9968 characters) supports that it is a substantial address rather than a brief announcement or notice.
2017-11-13 English
Results of Meeting 2 pages 101.3KB
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is an ASX/Media Release dated 14 November 2017, titled 'Results of Annual General Meeting'. It reports the outcomes of shareholder votes on various resolutions, including adoption of the remuneration report, re-election of a director, and approval of placement capacity. The content focuses on the voting results from the AGM and does not contain financial statements or detailed financial analysis. The document length is 2730 characters, which is relatively short and consistent with a voting results announcement rather than a full report. Therefore, this document fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2017-11-13 English
Investor Presentation 29 pages 2.0MB
Investor Presentation Classification · 100% confidence The document is titled 'Investor Presentation' and is described as an updated investor presentation to be presented at the company's AGM and during a roadshow. It contains detailed information about the company's business, clinical programs, market positioning, leadership, and financial overview. The content is typical of an investor presentation aimed at providing investors with a comprehensive update on the company's strategy, progress, and outlook. There is no indication that this is a regulatory filing, earnings release, or annual/interim report. The document length is substantial (15,000 characters), and it is not merely an announcement of a report but the report itself. Therefore, the appropriate classification is 'Investor Presentation' (IP).
2017-11-12 English
Botanix Commences BTX 1204 Dermatitis Patient Study 3 pages 115.4KB
Regulatory Filings Classification · 95% confidence The document is an ASX/Media Release dated 31 October 2017 announcing the commencement of a clinical patient study for Botanix Pharmaceuticals' BTX 1204 atopic dermatitis program. It details the study design, expected timeline, and background on the product and company. There are no financial statements, regulatory filings, or detailed financial data present. The content is primarily an announcement of a clinical trial start, not a financial report or regulatory filing. Therefore, it fits best under the category of a general Regulatory Filing (RNS) as it is a company announcement to the market that does not fit other specific categories.
2017-10-30 English
Appendix 4C - quarterly 9 pages 542.8KB
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Botanix Pharmaceuticals 4C Quarterly Cash Flow Report' and is dated 31 October 2017, covering the quarter ending 30 September 2017. It includes detailed financial data such as consolidated statements of cash flows, operating activities, and investing activities. The mention of 'Appendix 4C Quarterly report for entities subject to Listing Rule 4.7B' indicates it is a regulatory quarterly cash flow report commonly used in Australian stock exchange filings. The document contains substantive financial data and analysis for a quarterly period, not just an announcement or summary. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q1 2018
2017-10-30 English
Notice of Annual General Meeting/Proxy Form 20 pages 989.8KB
AGM Information Classification · 100% confidence The document is titled 'NOTICE OF ANNUAL GENERAL MEETING AND EXPLANATORY MEMORANDUM' for Botanix Pharmaceuticals Limited. It includes details about the AGM date, location, agenda items such as receiving and considering the annual financial report, adoption of the remuneration report, re-election of a director, and approval of placement capacity. It also contains proxy voting instructions and explanatory notes for shareholders. The document is clearly a notice and explanatory memorandum for an upcoming Annual General Meeting, not the actual annual report or financial statements themselves. Therefore, it fits the category of AGM Information (AGM-R). The document length is substantial (15,000 characters), consistent with detailed AGM notices and explanatory memoranda.
2017-10-12 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.